Oculis Revenue and Competitors
Estimated Revenue & Valuation
- Oculis's estimated annual revenue is currently $10.2M per year.
- Oculis's estimated revenue per employee is $155,000
- Oculis's total funding is $2M.
Employee Data
- Oculis has 66 Employees.
- Oculis grew their employee count by 32% last year.
Oculis's People
Name | Title | Email/Phone |
---|---|---|
1 | CEO | Reveal Email/Phone |
2 | CEO | Reveal Email/Phone |
3 | Chief Strategy Officer | Reveal Email/Phone |
4 | Chief Commercial Officer | Reveal Email/Phone |
5 | Chief Technology Officer | Reveal Email/Phone |
6 | VP, Clinical Operations | Reveal Email/Phone |
7 | VP, Head Supply Chain | Reveal Email/Phone |
8 | VP, Strategic Marketing, BD&L and Corporate Communications | Reveal Email/Phone |
9 | VP Financial and SEC Reporting | Reveal Email/Phone |
10 | Chief Financial Officer | Reveal Email/Phone |
Oculis Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $99.4M | 458 | 40% | N/A | N/A |
#2 | $20.6M | 133 | 22% | N/A | N/A |
#3 | $156.1M | 146 | -70% | $145M | N/A |
#4 | $3.5M | 45 | -25% | $150M | N/A |
#5 | $1.6M | 21 | 0% | $459.5M | N/A |
#6 | $67.3M | 310 | 16% | $180.7M | N/A |
#7 | $8.5M | 55 | -2% | N/A | N/A |
#8 | $256.3M | 1025 | 9% | $168.5M | N/A |
#9 | $2.8M | 18 | -33% | N/A | N/A |
#10 | $9.1M | 59 | -9% | N/A | N/A |
What Is Oculis?
Oculis is a clinical stage biopharmaceutical company whose mission is to develop novel topical treatments (eye drops) for ophthalmic diseases for both back- and front-of-the-eye in order to improve the lives of patients worldwide. INNOVATIVE TOPICAL THERAPIES FOR MILLIONS OF PATIENTS WORLDWIDE The Oculis strategy is to build a specialty ophthalmology company unlike any other. Our plan is to further advance our lead candidate, OC-118, for commercialisation as a new therapeutic option for DME patients and to develop a clinical pipeline of topical treatments for back- and front-of the-eye disease based on internal development with our proprietary SNP technology and via complementary in-licensed assets OC-118 A POTENTIAL PARADIGM SHIFT IN DME TREATMENT Our most advanced product candidate based on SNP technology is OC-118, which is in clinical trials in patients with DME and in planning phase for potential front-of-the-eye indications. If approved in DME, it has the potential to provide a new option for patients for whose current therapies are limited to intravitreal injections or implants. TAKING TREATMENT FROM INJECTIONS TO DROPS FOR BACK-OF-THE-EYE DISEASES Our novel technology provides an unprecedented technical advancement in ocular drug delivery, particularly for back-of-the-eye diseases that are currently managed by invasive methods such as intraocular injections or implants.
keywords:N/A$2M
Total Funding
66
Number of Employees
$10.2M
Revenue (est)
32%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Oculis News
... Novel and Emerging Therapeutic Drugs, Clinical Trials, and Treatment Outlook | Key Companies-Oculis, Formosa Pharma, Tarsius, and Others.
For example, in an environment populated by injectable treatments that address part of the condition, Oculis is developing topical therapeutics...
Oculis is a global biopharmaceutical company purposefully driven to save sight, improve eye care and address significant unmet medical needs...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $7.7M | 66 | 6% | N/A |
#2 | $10.5M | 66 | 2% | N/A |
#3 | $9.9M | 71 | 22% | N/A |
#4 | $9.4M | 72 | 4% | N/A |
#5 | $25.4M | 73 | 20% | N/A |